Dx Vx (DXVX) Partners with Over 40 Global Companies at BIO USA, "Focused Discussions on Overseas Out-Licensing Deals"
- Written by PR Newswire
- Oral obesity drug with world-first mechanism of action unveiled, drawing strong on-site interest
- Following successful Phase 1 clinical results, global discussions on OVM-200 expand
- Meetings with over 40 companies, including major pharmaceutical companies, out-licensing now within reach
SEOUL, South Korea, July 6, 2026 /PRNewswire/ -- Dx&Vx has...
